Sermorelin
GHRH(1-29), The Peptide That Was FDA-Approved, Then Discontinued
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA-approved as Geref (1997), discontinued 2008; now compounded
Reference only. Not medical advice.
What can go wrong
GH-stimulation risks apply: fluid retention, joint aches, insulin-resistance signals, and elevated IGF-1. As a compounded product, potency and purity depend entirely on the pharmacy. The historical FDA approval does not extend to today's anti-aging compounded formulations or their marketed claims.
This is something to take to a clinician. The Atlas can tell you what is known about sermorelin in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Sermorelin is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone GHRH(1-29), the fragment that retains full GHRH activity. Unlike most peptides in the optimization market, sermorelin has a genuine FDA history: it was approved as a diagnostic agent for GH deficiency and later (as Geref) for pediatric idiopathic GH deficiency, before manufacturer EMD Serono voluntarily discontinued it in 2008 for commercial, not safety, reasons. It survives today almost entirely through compounding pharmacies marketing it for anti-aging.
The one anti-aging GH-releasing peptide with a real FDA history, for a different use.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Sermorelin binds pituitary GHRH receptors and stimulates the gland's own pulsatile GH secretion. Because it works through the intact pituitary and preserves negative feedback, proponents describe it as more physiologic than injecting recombinant GH directly.
A real approval history, repurposed for an unproven claim
Sermorelin genuinely cleared FDA review, but for pediatric GH deficiency and diagnostic testing, not for anti-aging, body recomposition, or 'optimization' in healthy adults. It was pulled from the market in 2008 because recombinant GH captured the pediatric indication and Geref became commercially unviable, per the manufacturer's own filing. The current adult anti-aging use is off-label, compounded, and not supported by outcome trials.
Replacement is not the same as a cycle
In children with documented GH deficiency, sermorelin was used to restore deficient GH signaling. In healthy adults it is used to push GH/IGF-1 above their own baseline, a fundamentally different, supraphysiologic and unproven application.
What people get wrong
Often said'Sermorelin is FDA-approved, so it's safe and proven for anti-aging.'
ActuallyIts FDA approval was for pediatric GH deficiency and diagnostics, and the product was discontinued in 2008. Adult anti-aging use is off-label and compounded, not FDA-endorsed.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Now supplied chiefly by compounding pharmacies; the branded FDA product no longer exists.
At a glance
- Amino acids
- 29 (GHRH 1-29)
- Brand (historical)
- Geref (Serono)
- FDA approved
- 1990 (diagnostic), 1997 (pediatric GHD)
- Discontinued
- 2008 (commercial reasons)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Sermorelin. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Geref (sermorelin) FDA approval / NDA 20-4431997
Approved for pediatric idiopathic GH deficiency
EMD Serono discontinuation letter to FDADec 2008
Withdrawal requested for commercial reasons; FDA later confirmed not withdrawn for safety/effectiveness